CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 42 enrolled
Drug / intervention
Docetaxel +3 moredrug
Likely dose
Docetaxel 75 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00658697
NCT00658697Phase 2Completed
CompareCT.gov

A Phase II Trial of Avastin, Docetaxel and Androgen Deprivation Followed by Continued Avastin and Androgen Deprivation for Men With a Rising Prostate Specific Antigen (PSA) After Local Therapy

Dana-Farber Cancer Institute·interventional·Posted Apr 15, 2008·Updated May 25, 2017

In Brief

A Phase 2 clinical trial evaluating Docetaxel, Bevacizumab, and 2 other interventions for Prostate Cancer. Completed, enrolled 42 participants across 3 sites.

Detailed Summary

In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising Prostate Specific Antigen (PSA) after treatment of their prostate cancer with surgery or radiation)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Beth Israel Deaconess Medical Center, Genentech, Inc.

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 15, 2008
Enrollment StartJun 1, 2008
Primary CompletionSep 1, 2014
Study CompletionJun 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.3 yearsPosted 18.2 years ago

Interventions

Docetaxeldrug

Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles

Bevacizumabdrug

Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles

ADTdrug

Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)

Bicalutamidedrug

Starting on day 84 orally once daily until hormone therapy is completed